What was Mirati Therapeutics’s price range in the past 12 months?
Mirati Therapeutics lowest stock price was €25.13 and its highest was €59.46 in the past 12 months.
What is Mirati Therapeutics’s market cap?
Currently, no data Available
When is Mirati Therapeutics’s upcoming earnings report date?
Mirati Therapeutics’s upcoming earnings report date is Feb 27, 2024 which is 60 days ago.
How were Mirati Therapeutics’s earnings last quarter?
Mirati Therapeutics released its earnings results on Nov 06, 2023. The company reported -€2.293 earnings per share for the quarter, beating the consensus estimate of -€2.61 by €0.317.
Mirati Therapeutics does not currently pay dividends.
What is Mirati Therapeutics’s EPS estimate?
Mirati Therapeutics’s EPS estimate is -€2.41.
How many shares outstanding does Mirati Therapeutics have?
Currently, no data Available
What happened to Mirati Therapeutics’s price movement after its last earnings report?
Mirati Therapeutics reported an EPS of -€2.293 in its last earnings report, beating expectations of -€2.61. Following the earnings report the stock price went down -0.693%.
Which hedge fund is a major shareholder of Mirati Therapeutics?
Among the largest hedge funds holding Mirati Therapeutics’s share is Baker Bros Advisors LP. It holds Mirati Therapeutics’s shares valued at 61M.
Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
Copying Jay Olson's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +40.28% per trade.